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Up to 50% of people with amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND), experience cognitive and/or behaviour changes, with 15% meeting the criteria for frontotemporal dementia (FTD). 1, 2 These changes represent a range of frontotemporal spectrum disorders in ALS (ALS-FTSD). 3 A genetic and pathological overlap between MND and FTD has been established with the C9orf72 repeat expansion occurring in ~6.3% of sporadic ALS cases, ~5.8% of sporadic FTD cases 4 and ~33% of familial MND cases, 5 and the TAR-DNA-binding protein occurring in almost all ALS, ALS-FTD and ~45% FTD cases. [6] [7] [8] Cognitive and behavioural symptoms in MND range from no impairment to cognitive impairment (ALSci), behavioural impairment (ALSbi), both (ALScbi) or ALS-FTD. 3 An association between neuropsychiatric disorders and ALS has previously been shown. 9, 10 Neuropsychiatric symptoms including schizophrenia, depression, anxiety and drug abuse or dependence are common in the years prior-to and following diagnosis in both ALS 10, 11 and behavioural variant FTD. 12 Genome wide association studies (GWAS) have revealed a modest genetic correlation between schizophrenia and ALS. 13 Furthermore, higher rates of psychosis, suicidal behaviour 14 and autism 15 have been shown in ALS patients' first and second-degree relatives, 14, 15 particularly in their children. 11 Despite evidence of an overlap of ALS-FTSD and neuropsychiatric disorders, it is unclear if neuropsychiatric disorders also contribute to the spectrum of cognitive and behavioural changes in ALS.
Using population-based data from the Scottish Clinical, Audit, Research and Evaluation of MND (CARE-MND) register, this study aimed to look at the association between cognitive and/or behavioural changes in MND as measured using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) 16 and neuropsychiatric disorders in MND kindreds'.
Specifically, we aimed to determine if the presence of cognitive and behaviour changes can be predicted by the patient's:
1. History of neuropsychiatric disorders 2. History of neuropsychiatric medication 3. Family history of neuropsychiatric disorders.
METHODS

Participants:
We studied people with MND (pwMND) registered on the CARE-MND platform, a population-based, prospective database of patients in Scotland diagnosed with MND. 17, 18 Since 2015, a major update of the register has taken place. Ethical approval was obtained for the original (MREC/98/0/56 1989-2010, 10/MRE00/78 2011-2015) and updated CARE-MND platform (Scotland A Research Ethics Committee, 15/SS/0126). Anonymised data for collaboration can be obtained upon reasonable request from the CARE-MND register. In Scotland, any patient receiving a diagnosis of MND (including ALS, and subtypes such as primary lateral sclerosis (PLS), progressive muscular atrophy (PMA) and progressive bulbar palsy (PBP)) is included on the register. pwMND can consent for their anonymised information to be used for research purposes. This study includes all consenting patients diagnosed with MND (240 ALS, 23 PLS, 9 PMA and 23 ALS-FTD) between January 2015 to January 2018 with ECAS data available.
Measures:
History of neuropsychiatric disorders
Neuropsychiatric history in patients:
We identified patients with a history of neuropsychiatric disorder (pre-or post-MND diagnosis) from data on the CARE-MND register, using medical history information. We assessed each patient on a case-by-case basis, and identified any relevant neuropsychiatric diagnoses (Table 1) . Each diagnosis was then categorised based on the International Classification of Diseases-10 (ICD-10). 19 We created a summary variable to indicate (yes/no) the presence of a relevant neuropsychiatric diagnosis for each individual. 
Neuropsychiatric medication history in patients:
We assessed each patient's medication history (pre-and post-MND diagnosis) to identify any relevant neuropsychiatric medication (supplementary eTable 1). We excluded medication typically used to treat the symptoms of MND (e.g. lorazepam) and cases where alternative or secondary use of the medication were stated (e.g. muscle cramps). We created a summary variable to indicate (yes/no) the presence of a relevant neuropsychiatric medication for each individual.
Family history of neuropsychiatric disorders:
Information on a family history of neuropsychiatric disorders (pre-MND diagnosis) was available on the CARE-MND register. These data were collected during routine clinical assessment around the time of MND diagnosis using a standardised proforma. Patients provided information on any family history of MND, dementia, neurological or neuropsychiatric disorders across four generations of blood relatives (patient's grandparents to children). We defined a positive family history as one or more relatives with a diagnosed neuropsychiatric disorder.
Cognition and Behaviour
ECAS cognitive and behaviour scores
Cognition and behaviour were measured using the ECAS. 16 This brief assessment, specifically designed for patients with motor degeneration, is both sensitive and specific to the types of impairments shown by ALS patients [20] [21] [22] [23] and is routinely undertaken in Scotland.
ECAS subscales are grouped into ALS specific domains (language, verbal fluency and executive functioning) and ALS non-specific domains (memory and visuospatial skills). A total score (max 136) and domain specific scores (ALS-Specific, max 100, ALS non-specific max 36) are calculated with established cut-offs indicating global and domain-specific impairment. The ECAS has been shown to be a sensitive and valid measure of cognition and behaviour in MND 16, 20 with good convergent validity with other screening tests. [21] [22] [23] [24] The ECAS behavioural interview was used to assess behaviour change across five domains based on behavioural-variant FTD diagnostic criteria: 25 disinhibition; apathy or inertia; loss of sympathy/empathy; perseveration and eating behaviour/hyperorality. The interview was completed by an informant, with a score of one indicating a behaviour change for that domain, with a maximum of five denoting the number of behavioural domains affected.
MND-FTSD subclasses
Using all available cognitive and behavioural data, we classified patients using the ALS-FTSD criteria. 3 We used published cut-offs for the ECAS total and ALS-specific scores 16 which have been shown to have maximum sensitivity and specificity to detect cognitive impairment against extensive gold standard neuropsychological assessment. 20 As we included all MND subtypes, we referred to these subclasses as MND-FTSD. Using this method, we identified those with cognitive (MNDci), behavioural (MNDbi) or both cognitive and behavioural impairment (MNDcbi). Cases of MND-FTD were identified on the CARE-MND register based on a diagnosis given by a neurologist during clinical examination.
The number of patients in some MND-FTSD subclasses was small for some analyses. To increase power, we collapsed the categories to identify patients with any type of cognitive Patients recruited to the CARE-MND register donated blood or saliva for genetic analysis.
C9orf72 genotyping was carried out using polymerase chain reaction (PCR) based on methods previously described. 26
Statistical Analysis:
Some participants had multiple ECAS scores available from repeat testing (n=39, max=3 entries). We included entries with the most complete data (n=23) and where the date of assessment was available (n=2). In cases where there were two entries within 6 months of each other (n=5), we used the first assessment to avoid potential practice effects. 27, 28 We examined predictors of cognitive and behavioural change in MND and given that these may increase during later stages of the disease, 29 we used the most recent ECAS entry for the remaining cases (n=9).
Dates of neuropsychiatric diagnosis and prescription of medication were available for some, but not all patients on the CARE-MND register. We focussed our analyses on all identified cases to increase statistical power. In addition, we conducted secondary analyses examining only those with confirmed premorbid information based on date of diagnosis or prescription of medication.
We examined the relationships between neuropsychiatric disorders, medication and family history and two outcomes: A) continuous cognitive and categorical (yes/no) behavioural ECAS scores and B) MND-FTSD subclasses, including the presence of any cognitive or behavioural impairment. The use of continuous scores increased statistical power to detect effects. However, the use of MND-FTSD subclasses to identify predictors of cognitive and/or behavioural impairments has important clinical implications. For analyses using continuous outcomes, we used linear regression and reverse log transformed ECAS scores where appropriate to avoid violation of normality. Results were back transformed for reporting. We examined the presence of each behaviour change using a series of binomial logistic regressions and MND-FTSD subclass using multinomial regression. For collapsed MND-FTSD subclasses indicating the presence of any cognitive or behaviour impairment, we used binomial logistic regression. Where appropriate, sensitivity analyses were conducted to determine if the associations were driven by MND-FTD cases and whether they remained after controlling for C9orf72 status. All analysis was conducted in R 30 and power calculations were conducted using the pwr package. 31
RESULTS
Information was available for 305 pwMND with ECAS data (mean age at diagnosis=62.26 years, SD=11.40, Table 2 ). 211 (69.2%) had complete cognitive and behavioural data, 82 
The relationship between patients' neuropsychiatric history and cognition and behaviour
Of the 305 people with ECAS data on the CARE-MND register, 60 patients had a medical history of a neuropsychiatric disorder. Those with and without a neuropsychiatric disorder did not differ on C9orf72 status (x 2 =0.098, p=0.755), however those with a neuropsychiatric disorder had a shorter disease duration at the time of ECAS (median=81 days) than those without (median=177 days; W=8458, p=0.005). No relationship was found between disease duration and total ECAS, ALS specific or ALS non-specific scores.
Mood disorders were the most common (n=42) followed by neurotic disorders (n=19), personality disorders (n=3), and schizophrenia, schizotypal and delusional disorder (n=1, Table 3 ). Based on diagnosis date, 39 had a definite premorbid neuropsychiatric disorder (2 were diagnosed post-MND diagnosis, 19 missing date). Those with a premorbid neuropsychiatric disorder had a shorter disease duration at the time of ECAS compared those without (77 vs 177 days, W=5583.5, p=0.006). There were no other significant differences on demographic or disease characteristics. Intentional self-harm 0 (0.00%) 0 (0.00%) 3 (8.30%) NOTE: Percentages are based on the number of people with neuropsychiatric disorders on the CARE-MND register (see n in each header). a Includes all cases of neuropsychiatric disorder regardless of date of diagnosis. b Includes neuropsychiatric disorders with a date of diagnosis prior to MND diagnosis only.
The analyses of ECAS scores revealed that a diagnosis of a mood disorder was associated with poorer language scores but no other specific subscale (Table 4 ). A diagnosis of any neuropsychiatric disorder was associated with increased likelihood of apathy but no other specific behavioural domain. Examination of each individual neuropsychiatric disorder showed an association between mood disorders and increased risk of apathy. We did not find any other significant associations between patient neuropsychiatric disorders and cognition or behaviour. After excluding MND-FTD cases, these associations were no longer significant.
After controlling for C9orf72 status, the association between mood disorders and language scores was no longer significant however all other associations remained. In secondary analysis examining those with confirmed premorbid neuropsychiatric disorders only (n=39), the association between mood disorders and apathy remained (supplementary eTable 2). The associations between mood disorders and language scores and any neuropsychiatric disorder and apathy were no longer significant; however, in both cases, statistical power was low (0.34 and 0.16 respectively).
The analyses of MND-FTSD classifications revealed that mood disorders were associated with increased odds of MNDbi vs MND with no impairment ( Table 5 ). This association remained after excluding MND-FTD cases and controlling for C9orf72 status. We did not find any other associations ( Table 5 and Figure 2a ) including those examining premorbid cases only (supplementary eTable 3 and eFigure 1a). 
The relationship between patients' history of neuropsychiatric medication and their cognition and behaviour
Of the 305 patients with ECAS data on the CARE-MND register, 127 had a relevant neuropsychiatric medication in their medical history (92 antidepressants, 54 benzodiazepines and 5 antipsychotics). Based on date of medication prescription and date of MND diagnosis, 25 people were identified with premorbid neuropsychiatric medication (57 were prescribed post-MND diagnosis and 45 missing dates). There were no significant differences between those with premorbid neuropsychiatric medication and those without on demographic or disease characteristics.
We found no associations between the prescription of any neuropsychiatric medication and cognition and/or behaviour changes (supplementary eTable 4), MND-FTSD subclass (supplementary eTable 5) or behaviour or cognitive impairment (eFigure 2). All results remained non-significant when including only those with medication prescribed prior to MND diagnosis (supplementary eTable 6-7 and eFigure1b).
The relationship between patients' family history of neuropsychiatric disorders and their cognition and behaviour
Of the 305 people with ECAS data on the CARE-MND register, information on family history of neuropsychiatric disorders was available for 231 (75.74%) patients. Patients with and without a family history of neuropsychiatric disorders did not differ on C9orf72 status (x 2 =3.209, p=0.073). A positive family history of any neuropsychiatric disorder was present in 36/231 (15.58%). Mood disorders was the most common (n=16) followed by schizophrenia, schizotypal or delusional disorders (n=10) and neurotic disorders (n=9, Table   3 ). A positive family history of dementia was reported in 76/266 (29%, data unavailable for 39) as was associated with increased odds of a family history of neuropsychiatric disorders (OR=4.198, 95%CI=1.996 to 8.958). There were no other differences between those with and without a family history of neuropsychiatric disorders on demographic or disease characteristics.
A family history of any neuropsychiatric disorders was associated with poorer visuospatial scores. A family history of mood disorder was significantly associated with poorer total ECAS and ALS non-specific scores, as well as poorer language, verbal fluency and visuospatial scores. For a family history of neurotic disorders, we found an association with poorer language and visuospatial scores ( Table 6 ). We did not find any other significant associations between family neuropsychiatric disorders and cognition or behaviour. After excluding MND-FTD cases, the association between family history of neurotic disorders and language scores remained (exp(B)=0.463, p=0.013). All other associations were no longer significant. All associations remained after controlling for C9orf72 status. For MND-FTSD subclass, a family history of any neuropsychiatric disorder was associated with an increased risk of MND-FTD and MNDbi versus MND with no impairment.
Examination of each neuropsychiatric disorder showed that a family history of mood and neurotic disorders were associated with an increased risk of MND-FTD versus MND with no impairment ( Table 7) .
The presence of any behaviour impairment was associated with a family history of any neuropsychiatric disorders or neurotic disorders (Figure 2b ). We did not find any associations between family history of neuropsychiatric disorders and the presence of any cognitive impairment. 
DISCUSSION
We showed that the associations between MND, FTD and neuropsychiatric disorders extend into the cognitive and behavioural features in MND. A premorbid mood disorder in an MND patient is associated with a 2.78 increase in the odds of apathy post-MND diagnosis and a family history of any neuropsychiatric disorder is associated with 3.14 and 5.08 increased odds of MNDbi and MND-FTD respectively. More specifically, a family history of mood disorder is associated with poorer overall cognition in addition to a 7.57 increase in the odds of MND-FTD. Patients with a family history of neurotic disorders are more likely to have poorer cognition, including language and visuospatial functioning, and a 13.75 increase in the odds of MND-FTD. These associations may contribute to the spectrum of cognitive and behavioural changes in MND.
Previous research has suggested that the C9orf72 expansion accounts for some of the shared predisposition between MND, FTD and neuropsychiatric disorders. In one study, C9orf72 was associated with higher rates of schizophrenia, suicide and autism in ALS and FTD family members. 32 Some studies have also shown an association between C9orf72 and cognition in ALS and FTD patients however these findings have been mixed. 33, 34 We showed that those with and without a personal or family history of neuropsychiatric disorders did not differ on C9orf72 status. To our knowledge, we are also the first to show that both patient and family neuropsychiatric history is associated with cognitive and behaviour changes in MND, independent of the patients C9orf72 status. These findings suggest that although a shared predisposition exists, factors other than C9orf72 status are contributing to this susceptibility. Furthermore, those with a premorbid neuropsychiatric disorder had a shorter disease duration at the time of ECAS assessment. This suggests that a neuropsychiatric history may be associated with poor cognition in the earlier stages of the disease however further research is needed to confirm this.
We showed associations across both ALS specific and non-specific cognitive domains.
Although ALS non-specific, including visuospatial impairment, are less common in MND, different cognitive profiles exist and other factors may be contributing. Impaired visuospatial skills are common in Alzheimer's Disease (AD) 35 therefore our results may reflect the presence of mild AD pathology. Alternatively, visuospatial skills have been shown to decline with increasing disease stage, even in FTD 35 therefore it may be an effect of disease stage.
Many associations did appear to be driven by MND-FTD patients and were no longer significant after removal of these cases. However, a family history of neurotic disorders and language scores remained significant after the removal of MND-FTD cases showing that these associations exist in non-demented MND patients. Furthermore, many associations were found with MNDbi and more specific cognitive deficits suggesting that neuropsychiatric history is associated with the full spectrum of cognitive and behavioural changes in MND. Future research using more in-depth measures of neuropsychiatric disorders, including subclinical symptoms, may be more sensitive and reveal further associations.
We were able to identify cases of premorbid neuropsychiatric disorders in MND patients using diagnosis date and found a strong relationship between premorbid mood disorders and apathy post-MND diagnosis. These findings suggest that a history of mood disorders may be a risk factor for the development of apathy in MND. Apathy or demotivation is the most common behavioural impairment in ALS. 36, 37 Although some symptoms of depression and apathy may overlap, a dissociation in ALS has been demonstrated 37 and the distinct profile of initiation apathy found in ALS has been related to a cognitive failure to initiate as demonstrated by verbal fluency deficits. 38 Early signs of apathy may have been captured as premorbid mood disorders on the CARE-MND platform. Little is known about timing of cognitive and behavioural symptoms relative to motor symptom onset in MND. However, these are likely to be mood disorders as only 7/28 (25%) cases were diagnosed with mood disorders in the 5 years prior to MND diagnosis.
Associations between neuropsychiatric history and later-life disease have previously been
demonstrated. An increased risk of dementia has been associated with a history of depression, anxiety, bipolar, schizophrenia and alcohol dependence. 39 Parkinson's Disease has also been associated with premorbid depression. 40 However, few studies have explored how premorbid neuropsychiatric disorders relate to cognitive and behavioural changes in neurodegenerative disease, including MND. The findings from this study highlight the contribution of neuropsychiatric symptoms to the cognitive and behavioural profiles in MND.
Our population-based study includes all MND patients in Scotland with cognitive and/or behavioural information assessed using the ECAS. This information allowed us to group patients using established cut-offs and the latest ALS-FTSD classifications. 3, 20 Rates of cognitive and/or behavioural impairment in our sample (156/305, 51.1%) were consistent with previous research. 1 We identified cases of MND-FTD based on neurologist diagnosis therefore they may not be in strict adherence to the ALS-FTSD criteria. 3 This may have contributed to fewer cases being identified than in previous research; however our rates (17/305, 5.57%) were comparable to published frequencies. 41 A classification of MND-FTD cannot be made using ECAS data available on the CARE-MND platform as information indicating progression of cognitive and/or behavioural symptoms, a key criterion, is unavailable. Based on the other two MND-FTD criteria 3 an additional 23 patients may have MND-FTD, however this could not be confirmed. The ECAS is generally administered shortly following diagnosis; however changes in cognition and behaviour have been shown to increase in the final stages of the disease 29 therefore some patients may go on to develop MND-FTD.
Neuropsychiatric disorders were uncommon in the MND kindreds included in our study. We identified mood disorders in 42 (13.77%) patients and 28 (9.18%) family members which is lower than expected based on previous research 14, 15 and rates found in the UK Biobank (27.20% of 123,000). 42 This resulted in small numbers in some analyses therefore these results should be interpreted cautiously. We were unable to examine associations with psychosis, schizophrenia or autism, neuropsychiatric disorders which have been shown to occur at higher rates in MND kindreds. 11, 14, 15 The number of patients with neuropsychiatric medication was higher than those with a neuropsychiatric history (127 vs 60). Information on the duration and reason for neuropsychiatric medication use was not available on the CARE-MND register. Therefore, cases were neuropsychiatric medication was prescribed to treat short-term symptoms not meeting diagnostic criteria or non-neuropsychiatric symptoms (e.g.
Duloxetine to treat fibromyalgia) may be been included. This may have contributed to the lack of associations found.
We used patient-reported family history data which may have contributed to the lower rates of neuropsychiatric disorders. The social stigma around mental health may prevent the sharing of this information and social and behavioural difficulties may lead to a loss of contact with family members. Furthermore 74/305 (24.26%) patients did not have any family history information. We may also have missed patient cases of neuropsychiatric disorders as we were unable to capture those: with subclinical symptoms not meeting traditional diagnostic criteria; without an official diagnosis; who did not seek medical treatment; with previously under recognised disorders (i.e. autism spectrum disorders). Future research using more comprehensive and complete family and patient data may reveal stronger associations.
C9orf72 status was available for 259 (85%) patients in this study, allowing us to account for this in secondary analysis. Although we showed that almost all associations between patient and family neuropsychiatric history, and cognition and behaviour remained after controlling for the patients C9orf72 status, we did not control for any other factors. Future studies may also include other confounding variables and other genes or whole genome sequencing previously associated with cognitive and behavioural impairment. 41 Furthermore, future research should include other patient groups and healthy controls to determine whether these associations are specific to MND.
Finally, we focused on results unadjusted for multiple comparisons increasing the risk of a false-positive result. This study is experimental and hypothesis generating therefore it is important to show unadjusted effects as these warrant further examination in future research. 43 However, unadjusted findings should be interpreted with caution. 
CONCLUSION
